edwards lifesciences news | Press Releases

Keyword	CPC	PCC	Volume	Score	Length of keyword
edwards lifesciences news	0.64	1	1311	90	25
edwards	0.6	0.7	1452	66	7
lifesciences	0.32	0.5	6178	3	12
news	0.35	0.4	3150	8	4

Keyword	CPC	PCC	Volume	Score
edwards lifesciences news	1.72	0.5	2522	36
edwards lifesciences newsroom	1.24	1	8954	22
edwards lifesciences news headlines	0.03	0.1	4127	92
edwards lifesciences stock news	0.08	0.1	4063	64
edwards lifesciences corporation news	0.09	0.3	6804	42
edwards lifesciences executive team	0.04	0.5	4157	39
ceo of edwards lifesciences	0.65	0.2	4358	42

Search Results related to edwards lifesciences news on Search Engine

Press Releases | Edwards Lifesciences
edwards.com

https://www.edwards.com/newsroom/press-releases

WEBFeb 2, 2024 · Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR. Read more. February 23, 2024.

DA: 71 PA: 37 MOZ Rank: 35

Edwards’ EVOQUE Valve Replacement System First …
edwards.com

https://www.edwards.com/newsroom/news/2024-02-02-edwards--evoque-valve-replacement-system-first-tra

WEBFeb 2, 2024 · IRVINE, Calif.-- (BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

DA: 25 PA: 64 MOZ Rank: 49

Edwards Lifesciences Reports Fourth Quarter Results
edwards.com

https://www.edwards.com/newsroom/news/2024-02-06-edwards-lifesciences-reports-fourth-quarter-result

WEBFeb 6, 2024 · IRVINE, Calif.-- (BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook. Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent. Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent.

DA: 13 PA: 95 MOZ Rank: 52

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY …
edwards.com

https://www.edwards.com/newsroom/news/2022-12-08-edwards-lifesciences-outlines-growth-strategy-at-a

WEBDec 8, 2022 · Reaffirming October 2022 financial guidance. Projecting 2023 global sales of $5.6 - $6.0 billion; underlying growth of 9% - 12% Projecting 2023 TAVR sales of $3.6 - $4.0 billion; underlying growth of 9% - 12% Projecting 2023 TMTT sales of $160 - $200 million. Estimating 2023 adjusted earnings per share of $2.45 - $2.60.

DA: 66 PA: 2 MOZ Rank: 41

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER …
edwards.com

https://www.edwards.com/newsroom/news/2023-10-25-edwards-lifesciences-reports-third-quarter-results

WEBSep 30, 2023 · IRVINE, Calif., Oct. 25, 2023 -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook. Q3 sales grew 12 percent to $1.48 billion; constant currency 1 sales grew 11 percent. Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent.

DA: 81 PA: 88 MOZ Rank: 75

Edwards Lifesciences Corp - Large, Real-world Studies …
edwards.com

https://ir.edwards.com/news/news-details/2024/Large-Real-world-Studies-Demonstrate-Continued-Excellent-Outcomes-for-Patients-Receiving-Edwards-SAPIEN-TAVR/default.aspx

WEBMar 11, 2024 · Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

DA: 68 PA: 79 MOZ Rank: 32

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY …
edwards.com

https://www.edwards.com/newsroom/news/2023-12-07-edwards-lifesciences-outlines-growth-strategy-at-a-cebe112

WEBIRVINE, Calif., Dec. 7, 2023 – Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance 1 today during its annual investor conference. Highlights of today’s conference include:

DA: 80 PA: 38 MOZ Rank: 55

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER …
edwards.com

https://ir.edwards.com/news/news-details/2022/EDWARDS-LIFESCIENCES-REPORTS-FOURTH-QUARTER-RESULTS/default.aspx

WEBIRVINE, Calif., Jan. 26, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook. 2021 sales grew 19 percent, or 18 percent on an underlying 1 basis. Q4 sales grew 12 percent to $1.33 billion; underlying 13 percent.

DA: 97 PA: 95 MOZ Rank: 53

Edwards Lifesciences Corp - Edwards’ EVOQUE Valve …
edwards.com

https://ir.edwards.com/news/news-details/2024/Edwards-EVOQUE-Valve-Replacement-System-First-Transcatheter-Therapy-to-Earn-FDA-Approval-for-Tricuspid-Valve/default.aspx

WEBFeb 02, 2024. Download. IRVINE, Calif.-- (BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

DA: 15 PA: 80 MOZ Rank: 18

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER …
edwards.com

https://ir.edwards.com/news/news-details/2022/EDWARDS-LIFESCIENCES-REPORTS-SECOND-QUARTER-RESULTS/default.aspx

WEBJun 30, 2022 · IRVINE, Calif., July 28, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights and Outlook. Q2 sales of $1.37 billion were flat versus an elevated prior year; underlying 1 sales grew 5 percent. Q2 TAVR sales grew 1 percent; underlying 5 …

DA: 13 PA: 6 MOZ Rank: 55